AstraZeneca PLC (ETR:ZEG)
130.05
+0.65 (0.50%)
Sep 19, 2025, 5:36 PM CET
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B USD in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$56.50B
Revenue Growth
+15.00%
P/S Ratio
4.18
Revenue / Employee
$599.16K
Employees
94,300
Market Cap
201.14B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Sartorius Aktiengesellschaft | 3.47B |
Fresenius Medical Care AG | 19.52B |
Fielmann Group AG | 2.40B |
Carl Zeiss Meditec AG | 2.18B |
AstraZeneca News
- 2 days ago - CEO At Rigel Pharmaceuticals Acquires Company Stock Options Worth $388K - Benzinga
- 2 days ago - Raymond Furey At Rigel Pharmaceuticals Secures Company Stock Options: $90K Acquired - Benzinga
- 2 days ago - Lisa Rojkjaer Enhances Portfolio With Rigel Pharmaceuticals Stock Options: $90K Acquired - Benzinga
- 2 days ago - Significant Move: David Santos Invests $90K In Rigel Pharmaceuticals Stock Options - Benzinga
- 2 days ago - Dean Schorno Makes Strategic Play: Invests $90K In Rigel Pharmaceuticals Stock Options - Benzinga
- 2 days ago - AstraZeneca (AZN) Reinforces Airsupra Benefits with New Clinical Data - GuruFocus
- 2 days ago - AstraZeneca : AIRSUPRA Gains FDA Label Update After Strong Results In Mild Asthma Patients - Nasdaq
- 2 days ago - Irelands pharma sector is world class, but why dont we have a Novo Nordisk to take our success to the next level? - Independent Ireland